Doctor of Osteopathy Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Norman Leopold

Neurology Chester, PA Doctor of Osteopathy

NPI 1740341569 CMS profile 33134

1 Medical Center Blvd, Suite 533, Chester, PA 19013

Open in the dashboard

General payments

$2,358

165 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Norman Leopold of Chester, PA is reported in the CMS Open Payments database as having received $2,358 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $417 29
2019 General $1,941 136

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Norman Leopold
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Norman Leopold were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Norman Leopold Neurology median Middle half National median
2019 $1,941 $474 $118–$2,177 $163
2020 $417 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Teva Pharmaceuticals USA, Inc. $575 55 payments
  2. Supernus Pharmaceuticals, Inc. $208 19 payments
  3. Sunovion Pharmaceuticals Inc. $173 12 payments
  4. Genzyme Corporation $125 6 payments
  5. Vertical Pharmaceuticals, LLC $119 8 payments
  6. Biogen, Inc. $110 7 payments
  7. Novartis Pharmaceuticals Corporation $107 5 payments
  8. UCB, Inc. $96 6 payments
  9. ACADIA Pharmaceuticals Inc $95 7 payments
  10. Amneal Pharmaceuticals LLC $89 6 payments
  11. Other $662 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $2,289 162 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $69 3 payments
Products named General payments · program years 2019–2020
  1. Ajovy Central Nervous System $405 40 payments
  2. APTIOM $173 12 payments
  3. OXTELLAR XR $145 13 payments
  4. AJOVY Central Nervous System $114 10 payments
  5. TECFIDERA $110 7 payments
  6. TYSABRI $103 6 payments
  7. Neupro $96 6 payments
  8. NUPLAZID $95 7 payments
  9. AVONEX $93 6 payments
  10. AIMOVIG $92 4 payments
  11. Other $1,183 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record